May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
In vitro Efficacy of Alternatives to Moxifloxacin and Gatifloxacin for Coagulase–Negative Staphylococcus (CNS)
Author Affiliations & Notes
  • T. Harper
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL
  • D. Miller
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL
  • H. Flynn, Jr
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL
  • Footnotes
    Commercial Relationships  T. Harper, None; D. Miller, None; H. Flynn, Jr., None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5555. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Harper, D. Miller, H. Flynn, Jr; In vitro Efficacy of Alternatives to Moxifloxacin and Gatifloxacin for Coagulase–Negative Staphylococcus (CNS) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5555.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Coagulase negative staphylococcus is the most common isolate in postoperative endophthalmitis. Fluoroquinolone antibiotics, especially moxifloxacin and gatifloxacin, are commonly used as prophylaxis against perioperative infection. As fluoroquinolone resistance is a growing concern, the purpose of this study is to compare the in vitro efficacy of gemifloxacin, linezolid, vancomycin, and quinupristin/dalfopristin to existing fluoroquinolones against human coagulase–negative staphylococcal (CNS) endophthalmitis isolates. Methods: Sample organisms from 35 CNS endophthalmitis isolates recovered between 1993 and 2004 were removed from the freezer and reconstituted. E–tests and disc diffusion methods were used to compare susceptibility patterns against gemifloxacin, moxifloxacin, gatifloxacin, linezolid, quinupristin/dalfopristin, and vancomycin. Inhibitory quotients (Cmax / MIC90) were calculated using published Cmax values. Cmax in this study is defined as the maximum attainable aqueous concentration using topical therapy. MIC90 is defined as the minimum concentration of antibiotic necessary to inhibit 90% of isolates. Results: The percent of CNS isolates susceptible are (in descending order): vancomycin (100%), linezolid (100%), quinupristin/dalfopristin (100%), gemifloxacin (88.6%), moxifloxacin (76.5%), and gatifloxacin (74.2%). The MIC90 values are (in decreasing order of efficacy): quinupristin/dalfopristin (0.75 µg/ml), vancomycin (3 µg/ml), linezolid (4 µg/ml), gemifloxacin (> 32 µg/ml), moxifloxacin (> 32 µg/ml), and gatifloxacin (> 32 µg/ml). Inhibitory quotients are: vancomycin (1.3), gatifloxacin (0.06), and moxifloxacin (0.008). Aqueous Cmax values for the other antibiotics in this study are unavailable. Conclusions: In the current study, vancomycin, linezolid, and quinupristin/dalfopristin were the most effective antibiotics against CNS. Moxifloxacin, gatifloxacin, and gemifloxacin were less effective and individually inhibited less than 90% of the isolates at concentrations measurable by the available E–tests. This suggests that fluoroquinolones may not offer ideal prophylaxis against coagulase–negative staphylococcus.

Keywords: endophthalmitis • antibiotics/antifungals/antiparasitics • Staphylococcus 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×